Cargando…

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients

Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin against CHE is not thoroughly investigated in Jap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakai, Masato, Suda, Goki, Ogawa, Koji, Yoshida, Sonoe, Hosoda, Shunichi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Ohara, Masatsugu, Sho, Takuya, Morikawa, Kenichi, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249214/ https://www.ncbi.nlm.nih.gov/pubmed/35776720 http://dx.doi.org/10.1371/journal.pone.0270786

Ejemplares similares

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
por: Nakai, Masato, et al.
Publicado: (2022)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
por: Kubo, Akinori, et al.
Publicado: (2021)

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2021)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021)

Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
por: Yoshida, Sonoe, et al.
Publicado: (2021)

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2022)

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication
por: Nakai, Masato, et al.
Publicado: (2022)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023)

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma
por: Ohara, Masatsugu, et al.
Publicado: (2023)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma
por: Kohya, Risako, et al.
Publicado: (2023)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
por: Kawagishi, Naoki, et al.
Publicado: (2022)

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2020)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases
por: Sho, Takuya, et al.
Publicado: (2018)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
por: Sho, Takuya, et al.
Publicado: (2022)

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy
por: Ishikawa, Toru, et al.
Publicado: (2020)

Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment
por: Suda, Goki, et al.
Publicado: (2016)

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
por: Sho, Takuya, et al.
Publicado: (2019)

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Treatment of hepatitis C in special populations
por: Suda, Goki, et al.
Publicado: (2018)

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
por: Sho, Takuya, et al.
Publicado: (2017)

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Methamphetamine-induced encephalopathy in the absence of hyperammonemia
por: Rabbany, Jessica M, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Therapy of hyperammonemia
por: Widera, Agata
Publicado: (2015)

Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Postbariatric Surgery Hyperammonemia: A Rare Cause of Encephalopathy
por: Castineira, Janyll, et al.
Publicado: (2019)

The Toll of Hyperammonemia on the Brain
por: Saunders, Justin M., et al.
Publicado: (2019)

Hyperammonemia Due to Empyema
por: Wada, Hiroshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3t2umne6hpt7rlbc714coak2e4